Suberanilohydroxamic acid aton pharma #digital #pharma

Posted On May 19 2017 by

#aton pharma


Suberanilohydroxamic acid aton pharma

  • Citations Citations 5
  • References References 31
  • It was reported that HDACi have multiple targets involved in RA. HDACi reduce the expression of some proinflammatory cytokines, especially TNF-a and IL-1 (Leoni et al. 2002; Chung et al. 2003; Johnstone, 2004; Nishida et al. 2004; Blanchard and Chipoy, 2005; Leoni et al. 2005); induce growth arrest and/or apoptosis of the transformed RA synovial cells through the upregulation of the cell-cycle inhibitor p21 (Waf/Cip1) (Chung et al. 2003; Nishida et al. 2004; Jungel et al. 2006); inhibit angiogenesis (Deroanne et al. 2002; Mie Lee et al. 2003; Kim et al. 2004; Michaelis et al. 2004; Qian et al. 2004); and decrease the expression of metalloproteinases (Mort, 2005; Young et al. 2005), all of which play an important role in bone and cartilage destruction in RA. All these mechanisms could provide beneficial effects in RA management.

[Show abstract] [Hide abstract] ABSTRACT: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Histone deacetylase inhibitors (HDACi), a new class of anti-cancer agents, have recently been reported to exhibit potent anti-inflammatory activities. A proof of concept study was carried out with suberoylanilide hydroxamic acid (SAHA) and MS-275, two HDACi currently undergoing clinical investigations for various oncological indications. The anti-rheumatic effects of SAHA and MS-275 were assessed in both mouse and rat collagen induced arthritis (CIA) models. SAHA exhibited moderate prophylactic efficacy. It attenuated paw swelling due to inflammation, decreased bone erosion in both mice and rats and reduced slightly the RA-induced bone resorption in rats. However, SAHA could not inhibit the onset of arthritis. In contrast, MS-275 displayed dramatic anti-rheumatic activities. In prophylactic intervention, high doses of MS-275 prevented bone erosion and markedly delayed the onset of arthritis; at low doses, MS-275 strongly attenuated paw swelling, bone erosion, and bone resorption associated with RA. Furthermore, the therapeutic efficacy of MS-275 was also documented. After the onset of arthritis, it could stop the disease progression and joint destruction. An anti inflammatory effect of MS-275 was also confirmed through its capacity to decrease serum IL-6 and IL-1beta levels in the CIA induced mouse model. The anti-rheumatic activity of MS-275 was also confirmed through histological observation. No synovial hyperplasia, pannus formation, cartilage or bone destruction were observed in the high dose prophylactic intervention in mice. This study strongly supported HDACi as an innovative therapeutic strategy for RA.

Full-text · Article · May 2007

[Show abstract] [Hide abstract] ABSTRACT: Histone reversible acetylation, which is controlled by histone acetyltransferases and deacetylases, plays a fundamental role in gene transcription. Histone deacetylase inhibitors (HDACIs), such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have been characterized not only as anticancer drugs, but also as cytodifferentiation-inducing agents. In human endometrium, postovulatory production of progesterone directs estrogen-primed endometrial glandular cells to differentiate and thereby produce a number of unique bioactive substances, including glycodelin, that are critical for implantation at the secretory phase of the menstrual cycle. In this study, we show that TSA and SAHA, belonging to the hydroxamic acid group of HDACIs, can induce the phenotype of a human endometrial adenocarcinoma cell line, Ishikawa (originally derived from the glandular component of the endometrium), to differentiate to closely resemble normal endometrial epithelium in a time- and dose-dependent manner, as determined by morphological changes, synthesis of glycogen, and expression of secretory phase-specific proteins, including glycodelin. The proliferation- and differentiation-modulating effects elicited by TSA and SAHA at their optimal concentrations were comparable or more potent than those exerted by combined treatment with progesterone and estradiol. Furthermore, the gene silencing of glycodelin by small interference RNA resulted in the blockade of HDACI-induced differentiation in Ishikawa cells, suggesting the requirement for glycodelin for endometrial epithelial differentiation. Our results collectively indicate that TSA and SAHA are potent differentiation inducers for endometrial glandular cells, providing a clue for a possible therapeutic strategy to modulate endometrial function by targeting glycodelin.

Full-text · Article · Jan 2006

Last Updated on: May 19th, 2017 at 12:17 pm, by

Written by admin

Leave a Reply

Your email address will not be published. Required fields are marked *